Teplizumab given first UK NHS dose to delay Stage 2 type 1 diabetes
A patient in Birmingham has become the first person in the UK to receive teplizumab on the NHS, marking a new approach to type 1 diabetes care that aims to slow disease progression before full insulin dependence begins. Annette Quilter, 42, from Shropshire, received the drug at Queen Elizabeth Hospital Birmingham after screening and assessment identified her as eligible following a summer diagnosis of Stage 2 type 1 diabetes.
The drug is designed for a very specific moment in the disease course: after the autoimmune process is already underway, but before the pancreas has lost enough insulin-producing capacity to make daily insulin unavoidable. In practical terms, that means the immune attack is still active, yet there is still enough beta-cell function left to preserve if the process can be interrupted or slowed. For patients, the result is not a cure. It is time — time to keep natural insulin production going longer, time to prepare for eventual insulin treatment, and time to live with a less abrupt transition into lifelong disease management.
Quilter described the diagnosis as a shock, but also as a turning point because the condition was detected early enough to make the new treatment an option. Her account captures the central promise of this intervention: if clinicians can identify people before insulin dependence develops, the disease trajectory can be altered before the most burdensome phase arrives.
How the drug works at the bedside
Type 1 diabetes develops when the immune system attacks the pancreas’ insulin-producing cells. Once those cells are destroyed, the body can no longer make enough insulin to regulate glucose, and patients must replace the missing hormone through injections or a pump. Teplizumab is aimed at the immune process driving that destruction. By slowing the immune system’s assault on pancreatic beta cells, it can extend the period before insulin is required.
Research trials have shown the treatment can halve the rate at which patients progress to needing insulin. That is a clinically meaningful shift because beta-cell decline in type 1 diabetes does not merely change laboratory values; it reshapes daily life. A delay in progression can reduce the urgency of insulin initiation, soften the psychological blow of diagnosis, and preserve residual endogenous insulin secretion for longer, which often helps with glucose stability.
The dosing schedule is intensive but short. Treatment involves one infusion a day for 14 consecutive days, with each infusion lasting about 30 minutes and followed by observation. That structure reflects the need to deliver immunomodulation in a controlled setting while monitoring for immediate reactions, even as the course itself is measured in days rather than months.
One sentence captures the clinical shift plainly: the aim is to postpone insulin-requiring disease, not merely improve numbers on a chart.
Why early identification matters for Stage 2 disease
Stage 2 type 1 diabetes sits in a particularly important window. The autoimmune process is already established, but patients have not yet crossed into the stage where insulin is fully required for survival. In that interval, screening and assessment become decisive, because the opportunity to intervene depends on identifying the condition before irreversible beta-cell loss accelerates.
Quilter was identified as eligible after screening, a reminder that the success of this strategy depends on systems as much as on pharmacology. A treatment that can delay progression only helps if patients are found early enough for the intervention to remain relevant. Her case also illustrates the emotional side of early diagnosis. For a general practitioner and mother of three, the value of extra time is not abstract; it changes how families plan around illness, work, and responsibility.
The NHS has made teplizumab available since June 2026 for eligible children over eight and adults with Stage 2 type 1 diabetes. That access brings a preventive immunotherapy model into routine care for a disease long managed only after insulin dependence is established. The shift is substantial because it moves attention upstream, toward preserving function rather than simply replacing what has already been lost.
Dr Danijela Tatovic of the University of Birmingham described the treatment as the product of years of research into early detection and intervention. Her comment reflects the biological logic behind the drug: if the immune system is the driver of destruction, then modifying that immune response before the pancreas is exhausted should buy meaningful clinical time. The goal is not to reverse the autoimmune process completely, but to slow its momentum enough to change the course of disease.
Matthew Metcalfe, executive director at QEHB, said Birmingham has long been at the forefront of diabetes research and praised the collaboration between clinicians, researchers and NHS organisations. That collaboration is central to how a treatment like this reaches patients. Early diagnosis, specialist assessment, infusion delivery, and post-dose observation all have to align, or the therapy remains an academic advance rather than a bedside reality.
For patients, the result is measured in breathing space. For clinicians, it is a signal that type 1 diabetes management is starting to include a pre-insulin phase in which immune therapy has a role. The unanswered operational question is how widely and how quickly eligible patients will be identified across the NHS, and how consistently the infrastructure for screening can match the therapy’s narrow window of benefit.